Researchers at the University of Cincinnati developed an approach to radionuclide therapy which uses engineered bacteria to target cancer cells without endogenously targetable receptors.
Both radiation and temozolomide, a generic chemotherapy treatment in pill form, have meaningful single-modality anti-tumor activity against slow-growing, low-grade gliomas.
